BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-81@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Sichuan Baili Pharmaceutical Co.\, Ltd. — BL-B01D1 [Dec 
 2026]
DESCRIPTION:Phase 3 primary completion: A Study Comparing BL-B01D1 With Doc
 etaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR W
 ild-type Non-small Cell Lung Cancer(PANKU-Lung02).\nSource: https://clinic
 altrials.gov/study/NCT06382129\nhttps://catalystbrief.girapphe.com/e/81?la
 ng=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/81?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
